1)McCowen KC,Smith RJ:Insulin-like growth factors.Kahn CR,et al(ed):Joslin's diabetes mellitus(14th ed),pp169-178,Lippincot Williams,2005
2)Kasayama S,et al:Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.Clin Endocrinol(Oxf)52:549-555,2000
3)Resmini E,et al:Secondary diabetes associated with principal endocrinopathies;The impact of new treatment modalities.Acta Diabetolol 46:85-95,2009
4)Mazziotti G,et al:Effects of somatostatin analogs on glucose homeostasis;A metaanalysis of acromegaly studies.J Clin Endocrinol Metab 94:1500-1508,2009
5)Colao A,et al:Glucose tolerance and somatostatin analog treatment in acromegaly;A 12-Month Study.J Clin Endocrinol Metab 94:2907-2914,2009
6)Piji H,et al:Bromocriptine;A novel approach to the treatment of type 2 diabetes.Diabetes Care 23:1154-1161,2000
7)Mazziotti G,et al:Diabetes in Cushing syndrome;Basic and clinical aspects.Trends Endocrinol Metab 22:499-506,2011
8)Schwartz SL,et al:Safety profile and metabolic effects of 14 days of treatment with DIO-902;Results of a phase Ⅱa multicenter,randomized,double-blind,placebo-controlled,parallel-group trial in patients with type 2 diabetes mellitus.Clin Ther 30:1081-1088,2008